Congratulations to Drs. Michael S. Okun and Adolfo Ramirez-Zamora on the publication of “Meta-Analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson’s Disease,” which appears in the September 24th issue of Movement Disorders: Clinical Practice.
ABSTRACT
Background
The association between newer classes of glucose-lowering drugs (GLDs) and risk of Parkinson’s disease (PD) remains unclear.
Objective
To examine the effect of newer GLDs on risk of PD through a meta-analysis of randomized outcome trials.
Methods
Included were randomized placebo-controlled outcome trials that reported PD events associated with three newer classes of GLDs (i.e., DPP-4 inhibitors, GLP-1RAs, and SGLT2 inhibitors) in participants with or without type 2 diabetes (T2D). The pooled odds ratio (OR) and 95% confidence interval (CI) were estimated using Peto’s method.
Results
The study included 24 trials involving 33 PD cases among 185,305 participants during a median follow-up of 2.2 years. Newer GLDs were significantly associated with a lower PD risk (OR, 0.50; 95%CI, 0.25–0.98) than placebo.
Conclusion
Newer GLDs may possibly be associated with a decreased risk of PD however larger datasets are required to confirm or refute this notion.